Sydney, Mar 16, 2006 AEST (ABN Newswire) - Leading cell therapy services company CyGenics Ltd. (ASX: CYN) announced that its US-based subsidiary, Cytomatrix LLC, had been granted US Patent 6991933, Cell Culture Spinner Flasks. This patent adds to the five already granted to the CyGenics group. A number of other patents are pending.
The patent is for the company's unique starwheel cell culture spinner flasks. These flasks provide an enhanced system for cell growth and improved secreted product yield by improving materials transfer via passive perfusion. The system can produce high concentrations of cells that can be used as targets for extraneous agent interaction such as viruses or stimulating compounds. Cells or modified cells grown in the system can be used to produce higher levels of secreted products while minimizing downstream processing.
The flasks are currently being used for research purposes and under license for small scale manufacture of specialized products.
The flasks are currently sold through the products arm of CyGenics, Cell Sciences and through a distributor in the US, BioMedical Resources, Northboro MA.
"Our system optimises research and small volume manufacture with the added benefit of a linearly scaleable path toward large volume manufacture system design," said Dr John Flickinger, President of Cytomatrix.
"A fully loaded system with a working volume of approximately 500 ml will produce at the level of a 5 L bioreactor on a small and easily manipulated foot print. This grant of patent reinforces CyGenics' intellectual property proposition, and protects us as we introduce these flasks into more markets around the world," said Steven Fang, CEO CyGenics. "I anticipate that this unique spinner system, employing our patented three-dimensional cellular growth scaffold, will continue to be well received by researchers and pharmaceutical companies".
Contact
Steven Fang, Group CEO, CyGenics Ltd
Ph : +61 (0)400 933 243
Email: steven.fang@cygenics.com
| ||
|
